To obtain basic evidence concerning the beneficial potential of PPARα ligand against MsPGN, we examined the glomerular protective effects of a PPARα agonist, clofibrate, in a well-established rat model of human MsPGN, anti-Thy1 nephritis. Here, THY1 is linked to nephritis.